The histamine H2 receptor antagonist lafutidine in Japanese patients with non-erosive reflux disease

Hepato-Gastroenterology

Volumn 57, Issue 104, 2010, Pages 1430-1434

  Inamori, Masahiko ^a   Iida, Hiroshi ^a   Hosono, Kunihiro ^a   Endo, Hiroki ^a   Sakamoto, Yasunari ^a   Takahashi, Hirokazu ^a   Koide, Tomoko ^a   Tokoro, Chikako ^a   Goto, Ayumu ^a   Abe, Yasunobu ^a   Hiratsuka, Noboru ^b   Nakajima, Atsushi ^a   Fujita, Masami ^c  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Hamacho Center Building Clinic   (Japan)

^c Shinanozaka Clinic   (Japan)

Author keywords

Histamine H2 receptor antagonist; Intragastric acidity; Lafutidine; Nonerosive reflux disease

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LAFUTIDINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGUS PH; FEMALE; GASTRIC PH MONITORING; GASTROINTESTINAL ENDOSCOPY; HEARTBURN; HUMAN; INFORMED CONSENT; JAPANESE; MALE; NON EROSIVE REFLUX DISEASE; PH MEASUREMENT; PRIORITY JOURNAL; TREATMENT DURATION;

ACETAMIDES; ADULT; AGED; ESOPHAGEAL PH MONITORING; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; JAPAN; MALE; MIDDLE AGED; PIPERIDINES; PYRIDINES; TREATMENT OUTCOME;

EID: 79952377530     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Inamori M, Togawa J, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Shimamura T, Kubota K, Sakaguchi T, Saito S, Ueno N, Nakajima A: Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? J Gastroenterol. 2005; 40: 453-8.
2. Iida H, Inamori M, Nozaki Y, Endo H, Hosono K, Akiyama T, Sakamoto Y, Takahashi H, Koide T, Tokoro C, Abe Y, Nakajima A: Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values. BMC Gastroenterology BMC Gastroenterol. 2009; 9: 52.
3. Inamori M, Akimoto K, Akiyama T, Fujita K, Takahashi H, Yoneda M, Abe Y, Kirikoshi H, Kubota K, Saito S, Ueno N, Nakajima A: Is Oral Combination Therapy with a Proton Pump Inhibitor and H2 Receptor Antagonist Effective as Initial Treatment? J Gastroenterol. 2007; 42: 510-1.
4. Sato H, Kawashima K, Yuki M, Kazumori H, Rumi MA, Ortega-Cava CF, Ishihara S, Kinoshita Y: Lafutidine, a novel histamine H2-receptor antagonist, increases serum calcitonin gene-related peptide in rats after water immersion-restraint stress. J Lab Clin Med. 2003; 141: 102-5. (Pubitemid 36216562)
5. Itoh H, Naito T, Takeyama M: Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma. Biol Pharm Bull. 2002; 25: 379-82. (Pubitemid 39663294)
6. Nishihara K, Nozawa Y, Nakano M, Ajioka H, Matsuura N: Sensitizing effects of lafutidine on CGRP-containing afferent nerves in the rat stomach. Br J Pharmacol. 2002; 135: 1487-94. (Pubitemid 34270920)
7. Onodera S, Shibata M, Tanaka M, Inaba N, Yamaura T, Ohnishi H: Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Jpn J Pharmacol. 1995; 68: 161-73.
8. Kawashima K, Ishihara S, Karim Rumi MA, Moriyama N, Kazumori H, Suetsugu H, Sato H, Fukuda R, Adachi K, Shibata M, Onodera S, Chiba T, Kinoshita Y: Localization of calcitonin gene-related peptide receptors in rat gastric mucosa. Peptides. 2002; 23: 955-66.
9. Hongo M, Kinoshita Y, Haruma K: A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. J Gastroenterol 2008; 43: 448-456. (Pubitemid 351997882)
10. Carlsson R, Dent J, Bolling-Sternevald E, Johnsson F, Junghard O, Lauritsen K, Riley S, Lundell L: The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol. 1998; 33: 1023-9. (Pubitemid 28505643)
11. Armstrong D, Bennett JR, Blum AL, Dent J, Dombal FTDe, Galmiche J P, Lundell L, Margulies M, Richter J E, Spechler S J, Tytgat G N, Wallin L: The endoscopic assessment of esophagitis: A progress report on observer agreement. Gastroenterology 1996; 111: 85-92.
12. Inamori M, Togawa J, Takahashi K, Yoneda M, Fujisawa N, Iwasaki T, Ozawa Y, Kikuchi T, Muramatsu K, Chiguchi G, Matsumoto S, Kawamura H, Abe Y, Kirikoshi H, Kobayashi N, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H: Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J Gastroenterol Hepatol. 2003; 18: 1034-1038.
13. Abe Y, Inamori M, Togawa J, Kikuchi T, Muramatsu K, Chiguchi G, Kawamura H, Kobayashi N, Kirikoshi H, Sakaguchi T, Takamura T, Nakajima A, Ueno N, Sekihara H: The comparative effects of single intravenous doses of omeprazole and famotidine on intragastric pH. J Gastroenterol. 2004; 39: 21-5.
14. Inamori M, Togawa J, Chiguchi G, Abe Y, Kikuchi T, Muramatsu K, Kawamura H, Kobayashi N, Kirikoshi H, Shimamura T, Sakaguchi T, Takamura T, Ueno N, Nakajima A: The Evaluation of Anti-secretory Drugs on Intragastric Acidity; Are the Combined Therapy of a Proton Pump Inhibitor and a H2 Receptor Antagonist Effective as an Initial Treatment? J Gastroenterol. 2005; 40: 213-4.
15. Inamori M, Akiyama T, Akimoto K, Takahashi H, Abe Y, Nakajima A: Evaluation of postprandial 3 h pH monitoring for gastroesophageal reflux disease: is there a possibility of streamlining the 24 h test? J Gastroenterol Hepatol. 2006; 21: 1761-2.
16. Iida H, Inamori M, Akimoto K, Mawatari H, Endo H, Nozaki Y, Akiyama T, Ikeda T, Sakamoto Y, Fujita K, Yoneda K, Takahashi H, Yoneda M, Goto A, Abe Y, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A: Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. Hepatogastroenterology. 2009; 56: 551-4.
17. Shimatani T, Inoue M, Kuroiwa T, Xu J, Nakamura M, Tazuma S, Ikawa K, Morikawa N: Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine. Dig Dis Sci. 2006; 51: 114-20. (Pubitemid 43106347)
18. Dimenas E: Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol Suppl 1993; 199: 18-21.
19. Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-8. (Pubitemid 28163170)
20. Prasad M, Rentz AM, Revicki DA: The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life. Pharmacoeconomics 2003; 21: 769-90. (Pubitemid 36976125)
21. Wiklund I, Bardhan KD, Müller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J, Scott M, Weir D, Fulton C, Gillon K, Peacock R: Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. Ital J Gastroenterol Hepatol 1998; 30: 19-27.
22. Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M, Willich SN: Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767-76. (Pubitemid 37323641)
23. van Pinxteren B, Numans ME, Bonis PA, Lau J: Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006; 3: CD002095.
24. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T: Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut 1997;41:452-8.
25. Tahir H, Sumii K, Haruma K, Tari A, Uemura N, Shimizu H, Sumioka M, Inaba Y, Kumamoto T, Matsumoto Y: A statistical evaluation on the age and sex distribution of basal serum gastrin and gastric acid secretion in subjects with or without peptic ulcer disease. Hiroshima J Med Sci 1984; 33: 125-30. (Pubitemid 14069199)
26. Feldman M, Richardson CT, Lam SK, Samloff IM: Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in occidental and oriental duodenal ulcer patients. Gastroenterology 1988; 95: 630-5.
27. Goldschmiedt M, Barnett CC, Schwarz BE, Karnes WE, Redfern JS, Feldman M: Effect of age on gastric acid secretion and serum gastrin concentrations in healthy men and women. Gastroenterology 1991; 101: 977-90.
28. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004; 2: 656-664. (Pubitemid 39013424)
29. Lind T, Havelund T, Carlsson R: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-979. (Pubitemid 27433659)
30. DeMeester TR, Wang CI, Wernly JA, Pellegrini CA, Little AG, Klementschitsch P, Bermudez G, Johnson LF, Skinner DB: Technique, indications, and clinical use of 24 hour esophageal pH monitoring. J Thorac Cardiovasc Surg 1980; 79: 656-670. (Pubitemid 10101864)
31. Schenk BE, Juipers EJ, Klinkenberg-Knol EC, Festen HP, Jansen EH, Tuynman HA, Schrijver M, Dieleman LA, Meuwissen SG: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 1997-2000.
32. Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO: Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599-1606. (Pubitemid 32523479)
33. Tack J, Fass R: Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther. 2004; 19 Suppl 1: 28-34. (Pubitemid 38253489)
34. Trimble KC, Farouk R, Pryde A, Douglas S, Heading RC: Heightened visceral sensation in functional gastrointestinal disease is not site-specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995; 40: 1607-1613.
35. Pehlivanov N, Liu J, Mittal R: Sustained esophageal contraction: a motor correlate of heartburn symptom. Am J Physiol Gastrointest Liver Physiol 2001; 281: G743-G751.
36. Ichikawa T, Ota H, Sugiyama A, Maruta F, Ikezawa T, Hotta K, Ishihara K: Effects of a novel histamine H2-receptor antagonist, lafutidine, on the mucus barrier of human gastric mucosa. J Gastroenterol Hepatol. 2007; 22: 1800-5. (Pubitemid 47525074)
37. Ichikawa T, Ishihara K, Saigenji K, Hotta K: Lafutidine-induced stimulation of mucin biosynthesis mediated by nitric oxide is limited to the surface mucous cells of rat gastric oxyntic mucosa. Life Sci. 1998; 62: PL259-64.
38. Ichikawa T, Ishihara K, Shibata M, Yamaura T, Saigenji K, Hotta K: Stimulation of mucin biosynthesis in rat gastric mucosa by FRG-8813 and its structural analogs. Eur J Pharmacol. 1996; 297: 87-92. (Pubitemid 26064512)
39. Ichikawa T, Ishihara K, Komuro Y, Kojima Y, Saigenji K, Hotta K: Effects of the new histamine H2 receptor antagonist, FRG-8813, on gastric mucin in rats with or without acidified ethanol-induced gastric damage. Life Sci. 1994; 54: PL159-64.
40. Saegusa Y, Ichikawa T, Iwai T, Goso Y, Ikezawa T, Nakano M, Shikama N, Saigenji K, Ishihara K: Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol. 2008; 43: 531-7. (Pubitemid 351536043)
41. Kan Y, Sakuma Y, Kato Y, Kotani J: Effects of an H2 receptor antagonist, lafutidine, on neuropathic pain in rats. J Osaka Dent Univ 2005; 39: 21-5.
42. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998; 21: 531-43. (Pubitemid 28475505)
43. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, Di Marzo V: An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci USA 2002; 99: 8400-5. (Pubitemid 34651064)
44. Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee CH, Sullivan JP, Faltynek CR: TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J Neurosci 2006; 26: 9385-93.
45. Toida M, Kato K, Makita H, Long NK, Takeda T, Hatakeyama D, Yamashita T, Shibata T: Palliative effect of lafutidine on oral burning sensation. J Oral Pathol Med. 2009; 38: 262-8.